INTENDED FOR UK AND IRELAND HEALTHCARE PROFESSIONALS HomePrescribing information
Quinsair® (levofloxacin hemihydrate) offers a well-established tolerability profile1

In a study comparing the efficacy and safety of Quinsair to tobramycin inhaled solution (TIS), Quinsair demonstrated an overall tolerability profile similar to tobramycin inhaled solution.2

  • Dysgeusia was a common adverse reaction.2-4
  • Dysgeusia had no apparent impact on adherence to Quinsair2
  • 95.5% of patients taking Quinsair completed treatment vs 99.1% of placebo-assigned patients, with similar reasons for discontinuation between treatment groups5

 

ADVERSE REACTIONS WITH AT LEAST A POSSIBLE CAUSAL RELATIONSHIP WITH QUINSAIR1



For the full list of Adverse Events, please see the UK Summary of Product Characteristics or the Ireland Summary of Product Characteristics.